P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION
2014; Elsevier BV; Volume: 60; Issue: 1 Linguagem: Inglês
10.1016/s0168-8278(14)61345-3
ISSN1600-0641
AutoresXavier Forns, Didier Samuel, David Mutimer, S. Fagiouli, Miguel Navasa, Kosh Agarwal, Marina Berenguer, Massimo Colombo, Kerstin Herzer, F. Nevens, Rodica Van Solingen‐Ristea, Dan Luo, Inge Dierynck, J. Witek,
Tópico(s)Liver Disease Diagnosis and Treatment
ResumoP1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION X. Forns, D. Samuel, D. Mutimer, S. Fagiouli, M. Navasa, K. Agarwal, M. Berenguer, M. Colombo, K. Herzer, F. Nevens, R. Van Solingen-Ristea, D. Luo, I. Dierynck, J. Witek. Liver Unit, Hospital Clinic, CIBEREHD and IDIBAPS, Barcelona, Spain; Centre Hepatobiliaire, Hospital Paul Brousse, University Paris South Villejuif, Paris, France; Queen Elizabeth Hospital and NIHR BRU, Birmingham, United Kingdom; Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Bergamo, Italy; Liver Unit, Hospital Clinic Barcelona, Barcelona, Spain; Kings College Hospital, London, United Kingdom; La Fe Hospital and CIBEREHD, Valencia, Spain; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; Liver Transplantation Unit, University Hospital Essen, Essen, Germany; University Hospitals KU Leuven, Leuven, Belgium; Janssen Research & Development, LLC, Titusville, NJ, United States; Janssen Infectious Diseases BVBA, Beerse, Belgium E-mail: xforns@clinic.ub.es
Referência(s)